S
Schülke • APEX Data Hub

Authorized Access Required

Dedicated data preview and decision support workbench for Schülke & Mayr Supply Chain Data Stewards.

Confidential • Phase 0 Discovery APEX-v3.4-DATA
A
APEX DECISION ENGINE
Phase 0 Tactical Discovery

Quick Wins Scenario Simulator & Decision Support Engine

Live Calculation Active (<100ms)

Interactive working capital scenario model calibrated for Schülke & Mayr's €56.34M inventory baseline. Adjust levers to simulate cash liberation, verify operational dispatch routing, inspect GxP regulatory boundaries, and prepare SAP MASS CSV uploads.

Dual-View Architecture (Jonas Stöckmann Directive)

Supply Planning Horizon:

Simulated Cash Released
2,642,887 €
Direct FCF Liquidity Impact
Working Capital Velocity
-18.4 Days
Days Inventory Out (DIO)
Hospital OTIF Protection
98.5%
Clinical SLA Guaranteed
QC Lab Lead Time
-5.0 Days
17.2d → 12.2d Quarantine

Parameter Levers (Phase 0)

1. Inactive Sediment Liquidation 60 %

Intercompany STO relocation & OTC pharmacy sell-off of >12M inactive stock

Recovered Cash: 1,605,096 €
2. Fast-Track QC Laboratory Compression 5 Days

Shorten batch testing & QP digital sign-off from 17.2d down to 12.2d

Recovered Cash: 782,885 €
3. Clinical OTIF Hospital Target 98.5% SLA

Stochastic quantile safety buffer optimization without breaching hospital contracts

Buffer Rationalization: 197,225 €
4. Blocked Inventory GxP Release 50 %

Deviation review clearance, 180-day biocide transition sell-off & relabeling

Recovered Cash: 176,801 €

APEX Decision Engine™

Autonomous Working Capital & GxP Steering
Target Balanced (Recommended)
Cross-Functional Tollgates (GxP / OTIF / ADR / SAP)

Operational Guardrail & Anticipation Status:

ALL GUARDRAILS PASSED (SAFE)
Lead Planner 101 Operational Concentration CAPACITY CO-PILOT

59.5% (€1.12M) of execution falls on Controller 101. Requires dedicated Phase 0 co-pilot to avoid manual SAP transaction backlog (ME21N / QA11).

Anticipated Data Blindspot [Gap #1]: Planner FTE workload constraints untracked in MARC extract.
Operational Routing:

Create intercompany STOs (Tx ME21N) to dispatch €1.61M of inactive finished goods from Werk 0001 (Norderstedt) to subsidiary warehouses in Poland (Plant 1090) and France (1140).

GxP & Lab Regulatory Boundary:

5-day reduction achieves 12.2-day turnaround. Hard stop: Ph.Eur. 14-day sterility incubation remains intact. Further compression requires rapid test validation (ATP bioluminescence).

Hospital OTIF & Clinical Impact:

Target OTIF 98.5% preserves emergency safety buffers for surgical antiseptics (desderman, octenisept) while rationalizing €197k of redundant buffers. Zero clinic contract risk.

Recommended SAP Action Codes:
ME21N (STO) QA11 (UD Release) MM02 (MARC-EISBE) MASS (CSV Upload)
Phased Free Cash Flow Realization Horizons: Model Exposure: €5.49M
Phase 0 Immediate Cash (W 4–8): €500,000 – €900,000 Priority QC releases + STO reallocation
12-Month Real Cash Flow: €2,000,000 – €3,400,000 Sediment replenishment freeze + buffer optimization
Planner 101 Concentration: 59.5% (€1.12M) of Top 20 Quick Wins belongs to Lead MRP Controller 101.
Double-Counting Safeguard: 14 quarantine lots (€1.55M) are also inactive sediment; releasing them from QA generates €0 cash without confirmed demand, requiring targeted STO relocation.
ETL Audit Note: -€203,830.47 decomposition variance and €3.17M inverted sign reporting error documented in NextGen source data.
Liquidity Share by Value Lever: STO: 60.7% • QC: 29.6% • Safety: 7.5% • Blocked: 6.7%
Dynamic Inventory Trajectory (M0 → M+4)

Werk 0001 Rolling Stock Projection: As-Is Baseline vs. APEX Target

Jonas Excel As-Is (-14.6%) APEX Optimized (-23.4%)
M0 (Current August) €33,271,874 Baseline Start
M+1 (September) €31,439,703 €29,820,000 -€1.62M STO Wave 1
M+2 (October) €30,849,609 €28,150,000 -€2.70M QC Release
M+3 (November) €29,375,025 €26,890,000 -€2.48M Buffer Reset
M+4 (December Target) €28,397,099 €25,480,000 +€2.91M Extra Cash
Real-Time Data Preview

Top Quick Win Material Positions (Live Recalculated)

Data Mirror Filters:
SKU Product Description Type Baseline Stock Simulated Cash Operational Dispatch Action SAP Tx Horizon
W000170001087 desderman 500 ml (DE) FERT 718,008 € + 447,483 € Intercompany STO transfer to Poland (Plant 1090) and France (1140) ME21N W 1–4
W0001121418 octenisept Wound-Desinf. 50 ml FERT 397,505 € + 355,056 € SLED monitoring & OTC pharmacy channel sell-off prior to expiry threshold VA01 / MM02 W 2–6
W0001121505 octenisan wash lotion 500 ml FERT 331,937 € + 239,937 € Fast-Track QC: microbiology release pathway compressed from 24 to 12 days QA11 / QA32 W 1–3
W0001644000 Dosing dispenser dosit des VERP 273,918 € + 202,223 € Bundling with disinfectant volume supply hospital tender contracts ME21N / VA01 W 2–4
W000170001037 desmanol care 1000 ml FERT 344,034 € + 194,554 € STO relocation of surplus stock to affiliates in Poland (1090) and Austria (1040) ME21N W 2–6
W000170003201 octenisan wash gloves INT FERT 393,560 € + 194,159 € Priority QP certification queue under EU GMP Annex 16 digital sign-off QA11 / QA32 W 1–2
W000112053 Phenoxyethanol Ph.Eur. (ROH) ROH 565,176 € + 175,500 € Fast-Track HPLC assay testing; instant charge feed into reactor synthesis QA11 W 1–2
Forensic Data Audit • SAP Schema Cleansing

10 Critical Data Gaps in Baseline Dataset & Phase 0 Ingestion Requirements

Download Forensic Audit Dossier (PDF)

Exhaustive technical analysis of the 10 data omissions in the NextGen Materialreport baseline. For each gap, inspect where it resides in SAP ERP, what operational/clinical risks it triggers, and the exact remediation required from Schülke's IT and Data Stewards.

P1 - Critical SAP: MCHB / MCHA

1. Missing Batch Shelf-Life & Expiry Dates (SLED)

Where it is Missing in SAP:

Table MCHB / MCHA • Field VFDAT (Shelf Life Expiration Date) • Tx MSC3N / MB5M

Operational & Clinical Impact:

Risk of dispatching lots with <180 days remaining shelf life to surgical clinics, causing shipment rejection, SLA penalties, and €7.41M SLOB write-offs instead of proactive STO re-allocation.

Phase 0 Ingestion Resolution:

Join MCHB-VFDAT on batch level; configure 180-day minimum hospital shelf-life buffer and FEFO dynamic routing.

P1 - Critical SAP: MAST / STPO

2. Missing Multi-Level BOMs & Component Linkages

Where it is Missing in SAP:

Table MAST / STPO • Field IDNRK (Component), MENGE (Quantity) • Tx CS03 / CS12

Operational & Clinical Impact:

Blind inventory reductions in raw materials (Octenidine API: €5.8M) or packaging (VERP: €3.9M, e.g. dispenser pumps) paralyze packaging lines of high-margin finished goods (FERT: €36.6M).

Phase 0 Ingestion Resolution:

Ingest multi-tier BOM explosion from MAST/STPO; lock critical component safety buffers before approving finished goods reductions.

P1 - Critical SAP: VBAP / VBBE

3. Unfulfilled Demand & Lost Sales Suppression

Where it is Missing in SAP:

Table VBAP / VBBE • Field ABGRU (Reason for Rejection), OMENG • Tx VA05 / MD04

Operational & Clinical Impact:

Stockout Death Spiral & The 'Infinite' Coverage Artifact: Billed sales suppress true demand, while 2,892 items (€20.67M = 36.7% of total stock) lack any forecast row, causing Power Query to assign '99999' (infinite coverage) and falsely tagging €3.34M in active finished goods (FERT) as non-moving sediment.

Phase 0 Ingestion Resolution:

Reconstitute true market demand by ingesting rejected order lines (ABGRU) and backorders from VBBE.

P2 - High SAP: MSEG / MKPF

4. Missing 24-Month Time-Series & Seasonality

Where it is Missing in SAP:

Table MSEG / MKPF • Field BWART (Movement Type), BUDAT (Posting Date) • Tx MB51 / MC.9

Operational & Clinical Impact:

€3.17M Reporting Label Defect & Seasonality Distortion: Column 'delta vs. last month' (-€2.84M) actually computes M-1 vs M-2 (instead of M0 vs M-1: +€334,915), creating a €3,172,418 swing with inverted sign that deceives management. Furthermore, flat annual averages blind planning to winter infection surges.

Phase 0 Ingestion Resolution:

Extract 24 months of historical material movements (movement types 101, 201, 261, 601) to calibrate seasonal multipliers.

P1 - Critical SAP: QALS / QAMV

5. QC Quarantine Diagnostics & LIMS Integration

Where it is Missing in SAP:

Table QALS / QAMV • Field STAT35 (Usage Decision), PRUEFLOS • Tx QA33 / QA11

Operational & Clinical Impact:

€5.42M detained for an average of 17.2 days without diagnostic root cause, risking regulatory non-compliance by confusing GMP-mandated 14-day sterility incubation with administrative delays.

Phase 0 Ingestion Resolution:

Decompose quarantine lead times into microbiological incubation (hard stop) vs HPLC chemical assays and Qualified Person sign-off queue.

P1 - Critical SAP: Regulatory MA

6. Missing Country Marketing Authorizations (MA)

Where it is Missing in SAP:

Table Regulatory MA • Field Country Code, Packaging PZN / CIP / PL • Tx Custom / MM03

Operational & Clinical Impact:

Criminal pharmaceutical offense: Transferring German-labeled octenisept (PZN) to Polish or French hospital subsidiaries without local registration dossier, language leaflet, or national packaging approval.

Phase 0 Ingestion Resolution:

Build regulatory authorization cross-reference table to hard-restrict STO replenishment suggestions to legally compliant product-market pairs.

P2 - High SAP: AFKO / AFPO

7. Shop Floor WIP & Reactor Changeover Sequencing

Where it is Missing in SAP:

Table AFKO / AFPO • Field GAMNG (Order Qty), AUFNR, CRHD (Work Center) • Tx COOIS / CM01

Operational & Clinical Impact:

Canceling or postponing production orders on lines that are already sanitized and set up generates equipment idle losses far exceeding inventory holding savings.

Phase 0 Ingestion Resolution:

Correlate inventory recommendations with open shop floor orders (AFKO) and plant-specific minimum batch compounding sizes.

P1 - Critical SAP: MARC

8. Master Data Defect: 34.1% SKUs with Lead Time = 0

Where it is Missing in SAP:

Table MARC • Field PLIFZ (Planned Delivery Time in Days) • Tx MM02 / SE16N

Operational & Clinical Impact:

1,895 active SKUs (34.1% / €19.3M) show Lead Time = 0 or blank (including 896 purchased items). Moreover, 'MRP lot size' (MARC-DISLS) is ambiguous: if it represents a procedure key rather than base lot quantity, the €2.8M batch-sizing saving requires recalibration.

Phase 0 Ingestion Resolution:

Batch update MARC-PLIFZ using historical measured vendor delivery lead times (or default empirical 21-day safety buffer).

P2 - High SAP: Hazardous Master

9. Hazardous Goods Storage Caps (ADR, ATEX, Seveso III)

Where it is Missing in SAP:

Table Hazardous Master • Field UN-Number (UN 1987), Flash Point, Storage Class • Tx WM / EWM

Operational & Clinical Impact:

Concentrating alcohol-based disinfectants in central hubs risks violating industrial fire safety permits and exceeding Seveso III upper-tier explosive volume thresholds.

Phase 0 Ingestion Resolution:

Embed site-specific flammable storage tonnage caps as hard linear optimization boundary constraints.

P2 - High SAP: Controlling Master

10. Uniform 15% Holding Cost Distortion

Where it is Missing in SAP:

Table Controlling Master • Field WACC + Category Specific Storage Rate • Tx CO-PC

Operational & Clinical Impact:

Balance Decomposition Gap (-€203,830.47 across 41 SKUs) & Omitted External Toll Stock: The 7 balance subcomponents (€56.54M) fail to reconcile with Valuated Stock (€56.34M) across all 120 combinatorial subsets. Additionally, €1,448,814.91 in toll stock (Provided to Supplier) is omitted, while flat 15% holding costs distort lot economics.

Phase 0 Ingestion Resolution:

Deploy differentiated holding cost schedule (2% to 28%) factoring in capital cost, cold storage, flammability, and shelf-life decay.

Pre-Offer Discovery & Scoping Checklist

20 Technical & Strategic Discovery Questions for Schülke Leads

Download Questions Checklist (PDF)

Structured questionnaire across 5 specialized corporate domains. Essential to align algorithmic optimization constraints, SAP technical extraction parameters, and Works Council co-determination requirements.

I. Supply Chain, MRP Planning & Customer Service Q#01

1. Frozen Planning Horizon

How many weeks in advance does Werk 0001 (Norderstedt) operate on a strictly frozen production schedule where MRP replenishment orders cannot be adjusted by algorithmic rebalancing (e.g. 2, 3, or 4 weeks)?

Target Stakeholder: VP Supply Chain / Planning Lead
Deliverable: Planning parameter table & freeze-fence calendar per packaging line.
I. Supply Chain, MRP Planning & Customer Service Q#02

2. Customer SLA & OTIF Penalties

What are the contractual minimum OTIF targets across customer tiers (surgical hospitals: 98–99%, pharmaceutical wholesalers: 95%, retail: 92%) and how are stockout penalties calculated?

Target Stakeholder: Head of Customer Service / Sales Operations
Deliverable: Customer segmentation SLA matrix & penalty schedule.
I. Supply Chain, MRP Planning & Customer Service Q#03

3. Inactive Sediment Stock Triage (€7.41M)

Of the €7.41M in sediment stock, what portion represents official Phase-Out items vs commercial inventory? Specifically, why does SKU 70001087 (desderman 500ml) exhibit AX classification and 53 days forward coverage, yet 73% is flagged as 1-year sediment (is sediment calculated at batch or SKU level)?

Target Stakeholder: Inventory Controller / Product Manager
Deliverable: Sediment SKU classification list with Phase-Out tags.
I. Supply Chain, MRP Planning & Customer Service Q#04

4. Planner Autonomy in SAP (MD04 / GIB)

Given that 59.5% of the Top 20 Quick Wins value (€1,123,464) is concentrated under Lead MRP Controller 101 (11 of 20 items), can the Phase 0 pilot rollout focus specifically on Planner 101's portfolio to maximize near-term traction? What autonomy do controllers have in MD04/GIB?

Target Stakeholder: Lead MRP Controller / GIB Superuser
Deliverable: Workflow authorization matrix for MRP parameter maintenance.
II. Quality Assurance, QC Lab & GxP Regime Q#05

5. Laboratory Bottleneck Breakdown (€5.42M Q-Stock)

What is the empirical distribution of the 17.2-day average quarantine duration across sample prep, microbiological incubation, HPLC/GC assay testing, and QP administrative sign-off?

Target Stakeholder: Head of Quality Control / Lab Operations
Deliverable: Cycle time decomposition histogram per analytical test type.
II. Quality Assurance, QC Lab & GxP Regime Q#06

6. Laboratory Information Management (LIMS)

Where is analytical sample status tracked in Werk 0001 (SAP QM inspection lots, dedicated LIMS like LabWare/Thermo Fisher, or spreadsheet logs)?

Target Stakeholder: QA Systems Manager / LIMS Lead
Deliverable: LIMS / SAP QM interface schema and inspection lot status codes.
II. Quality Assurance, QC Lab & GxP Regime Q#07

7. Digital Review-by-Exception Protocol

Does QA endorse a 'Review-by-Exception' workflow enabling instant, priority batch release for standard lots without OOS/OOT deviations based on digital Certificate of Analysis summaries?

Target Stakeholder: Qualified Person (QP) / Head of Quality Assurance
Deliverable: QA policy statement on digital deviation filtering.
II. Quality Assurance, QC Lab & GxP Regime Q#08

8. Software Validation Strategy (CSV vs FDA CSA)

Does QA mandate full V-Model CSV (GAMP 5) for analytics advisory models, or does it accept modern FDA Computer Software Assurance (CSA) principles for non-GxP decision support?

Target Stakeholder: Head of IT Compliance & Computer System Validation
Deliverable: Validation master plan governance guidelines.
III. External Procurement, Vendors & MOQ Q#09

9. Procurement Blanket Order Contracts (€31.65M)

Can rigid purchase orders for raw materials (ROH: €5.8M) and packaging (VERP: €3.9M) be transitioned into blanket orders with delivery schedules in SAP transaction ME38?

Target Stakeholder: Head of Direct Procurement / Category Managers
Deliverable: Vendor contract type breakdown & call-off feasibility matrix.
III. External Procurement, Vendors & MOQ Q#10

10. Vendor-Managed Inventory (VMI) Feasibility

Can Schülke establish consignment stock agreements (§ 6b UStG in Germany / Art. 12a VAT in Poland) for its top 5 chemical and plastic canister packaging suppliers?

Target Stakeholder: Strategic Sourcing / Logistics Procurement
Deliverable: Top 10 supplier spend ranking with consignment eligibility assessment.
III. External Procurement, Vendors & MOQ Q#11

11. Root Cause of 0-Day Lead Times (34.1% SKUs)

What operational factor causes 1,895 active SKUs to show 0 days planned delivery time in MARC-PLIFZ? Is this unmaintained legacy master data or supplier unreliability?

Target Stakeholder: Master Data Steward / Procurement Controller
Deliverable: Cleansing backlog list for table MARC field PLIFZ.
III. External Procurement, Vendors & MOQ Q#12

12. Packaging Component Standardization

Is it technologically feasible to standardize bottle neck finishes and dispenser pump formats across disinfectant brands to reduce unique SKU count and supplier MOQ hurdles?

Target Stakeholder: Packaging Engineering / Procurement Lead
Deliverable: Packaging compatibility matrix & MOQ reduction plan.
IV. IT Architecture, SAP Integration & Security Q#13

13. Automated Delta Background Export (SM36)

Can IT configure a recurring background job (SM36) in SAP to export weekly inventory snapshots (identical to NextGen Materialreport) to an encrypted SFTP server?

Target Stakeholder: SAP Basis Administrator / Integration Architect
Deliverable: SFTP connection profile & SM36 batch job schedule.
IV. IT Architecture, SAP Integration & Security Q#14

14. Production SAP ERP Release & GIB Modules

What is the exact release of SAP (ECC 6.0 vs S/4HANA) and active GIB modules? Critically: does the column 'MRP lot size' in NextGen report originate from MARC-DISLS (procedure key like EX, FX) or actual fixed/minimum order quantities (BSTFE/BSTMI)?

Target Stakeholder: Enterprise IT Architect / SAP Application Manager
Deliverable: System landscape diagram (SPRO) & GIB module licensing map.
IV. IT Architecture, SAP Integration & Security Q#15

15. Mass Maintenance Authorizations (MASS / MM17)

Do supply chain controllers have authorizations to upload batch safety stock parameters into table MARC using standard SAP transactions (MASS, MM17, or LSMW)?

Target Stakeholder: SAP Security & Authorization Lead
Deliverable: User authorization profile (PFCG) for mass maintenance.
IV. IT Architecture, SAP Integration & Security Q#16

16. Quality Assurance Sandbox Access (QAS)

Will the project team be provided access to an anonymized staging environment (QAS) for validating algorithmic dispatch rules during Phase 1 MVP?

Target Stakeholder: Head of IT Infrastructure & Project Management Office
Deliverable: Sandbox credential provisioning schedule & anonymization sign-off.
V. Finance, Strategy & Works Council Q#17

17. Internal Holding Cost Rate

What annual percentage rate does corporate controlling apply as the true inventory carrying cost (e.g. 15%, 18%, or 20%), factoring in WACC, storage overhead, and scrap write-offs?

Target Stakeholder: Chief Financial Officer (CFO) / Head of Controlling
Deliverable: Controlling handbook excerpt on working capital carrying rates.
V. Finance, Strategy & Works Council Q#18

18. Gain-Share Baseline Metric Definition

Does the Steering Committee adopt the phased cash release targets: €0.5–0.9M in Phase 0 (Weeks 4–8), scaling to €2.0–3.4M in 12 months, and agree to deduct the 14 overlapping quarantine/sediment SKUs (€1.55M) to prevent double-counting between QC release and stock liquidation?

Target Stakeholder: CFO / Private Equity Investment Director
Deliverable: Financial baseline definition agreement.
V. Finance, Strategy & Works Council Q#19

19. Works Council Alignment (Betriebsrat Norderstedt)

Has the AI inventory copilot initiative been formally presented to the Norderstedt Betriebsrat under § 87 Abs. 1 Nr. 6 BetrVG, and is an overarching IT framework agreement in effect?

Target Stakeholder: Head of Human Resources & Labor Relations
Deliverable: Betriebsrat scoping memo & draft co-determination agreement.
V. Finance, Strategy & Works Council Q#20

20. C-Suite Strategic Focus for Upcoming Quarter

What is the primary executive priority: maximizing near-term Free Cash Flow for PE sponsors, reducing operational P&L holding costs, or guaranteeing zero-risk hospital delivery security?

Target Stakeholder: Chief Executive Officer (CEO) / Managing Director
Deliverable: Executive priority weighting statement.
Execution Register • Granular 20 SKU Master Ledger

Master Execution Ledger – 20 High-Priority Quick Win Initiatives (€3.86M Initial Recovery)

Full granular execution table for Schülke's dispatchers and data stewards. Values dynamically reflect the active simulator levers. Includes specific SAP transactions (ME21N, QA11, MM02, CO02) and operational step-by-step instructions.

SKU Product Description Type Baseline Stock Simulated Cash (€) Operational SAP Dispatch Plan Target Tx Horizon
W000170001087 desderman 500 ml (DE) STO FERT 718,008 € + 447,483 € Intercompany STO transfer to Poland (Plant 1090) and France (1140) ME21N W 1–4
Operational Instruction: Execute cross-border stock transport order in ME21N; verify bilingual label compliance before booking 351 movement.
W0001121418 octenisept Wound-Desinf. 50 ml STO FERT 397,505 € + 355,056 € SLED monitoring & OTC pharmacy channel sell-off prior to expiry threshold VA01 / MM02 W 2–6
Operational Instruction: Route batches with 180-270 days remaining shelf life to retail wholesalers via OTC sales order pricing condition.
W0001121505 octenisan wash lotion 500 ml QC FERT 331,937 € + 239,937 € Fast-Track QC: microbiology release pathway compressed from 24 to 12 days QA11 / QA32 W 1–3
Operational Instruction: Fast-track incubation readouts in QA32; record usage decision immediately post Ph.Eur. 12-day incubation.
W0001644000 Dosing dispenser dosit des STO VERP 273,918 € + 202,223 € Bundling with disinfectant volume supply hospital tender contracts ME21N / VA01 W 2–4
Operational Instruction: Bundle excess hardware dispensers as complimentary incentives in long-term hospital supply agreements.
W000170001037 desmanol care 1000 ml STO FERT 344,034 € + 194,554 € STO relocation of surplus stock to affiliates in Poland (1090) and Austria (1040) ME21N W 2–6
Operational Instruction: Offset local Polish hospital backorders by transferring Norderstedt safety surplus via STO.
W000170003201 octenisan wash gloves INT QC FERT 393,560 € + 194,159 € Priority QP certification queue under EU GMP Annex 16 digital sign-off QA11 / QA32 W 1–2
Operational Instruction: Implement digital CoA verification queue for Qualified Person sign-off to eliminate 4-day desk queue.
W000112053 Phenoxyethanol Ph.Eur. (ROH) QC ROH 565,176 € + 175,500 € Fast-Track HPLC assay testing; instant charge feed into reactor synthesis QA11 W 1–2
Operational Instruction: Accelerate raw material release to unblock synthesis schedule for finished disinfectants.
W000110000374 Octenidine Dihydrochloride (API) QC ROH (QC) 290,382 € + 173,288 € Immediate release of critical active pharmaceutical ingredient (API) QA11 W 1–3
Operational Instruction: High-capital active ingredient. Expedite Certificate of Analysis to feed compounding reactors.
W0001104804 kodan tincture forte coloured 1L STO FERT 258,548 € + 166,386 € Dynamic FEFO allocation; priority dispatch to hospitals before SLED expiration ME21N / VL01N W 3–6
Operational Instruction: Assign shortest shelf life batches to high-volume university clinics with >95% monthly burn rate.
W000170000788 schülke wipes s&e bagless STO FERT 311,020 € + 153,254 € Allocation into multi-year public healthcare hospital tender tenders VA01 W 4–8
Operational Instruction: Integrate non-moving wipe stock into group tender delivery tranches across Nordrhein-Westfalen.
W0001123301 octeniderm colourless 1000 ml STO FERT 284,100 € + 148,508 € Intercompany STO transfer to France affiliate (Plant 1140) ME21N W 2–4
Operational Instruction: Cross-border reallocation under French marketing authorization to eliminate local stockouts.
W0001107122 mikrozid liquid Bulk f.AH STO FERT 210,400 € + 125,871 € Sequencing into active packaging line schedule; bulk stock clearance CO02 W 1–2
Operational Instruction: Schedule bulk solution into immediate bottle filling run to liberate IBC container capacity.
W000170002875 mikrozid universal wipes prem SS FERT 182,500 € + 85,127 € Excess AX safety buffer; recalibration to 20 days in MARC-EISBE MM02 / MASS W 1–2
Operational Instruction: Recalibrate safety stock from 45 to 20 days; demand coefficient of variation is stable at 0.18.
W000170002876 mikrozid univ wipes prem maxi SS FERT 148,200 € + 64,577 € Stochastic quantile recalibration of safety stock (98.5% SLA) MM02 / MASS W 2–3
Operational Instruction: Adjust reorder point parameter in MARC-MINBE to align with true replenishment lead time.
W1090109302 mikrozid AF liquid EU-A BLOCK FERT 105,513 € + 56,802 € Sell-off execution under 180-day biocide transition statutory window QA11 / MB1B W 2–6
Operational Instruction: Legally authorized emergency clearance window; reclassify stock via movement 343 to unrestricted.
W000110000369 Octenidin - Helm Lebsa BLOCK ROH 62,828 € + 47,121 € Controlled batch blending and assay testing under QA oversight QA11 W 2–4
Operational Instruction: Blend blocked sub-potency lot with virgin active batch to meet monograph specification.
W000170000812 mikrozid PAA+ wipes BLOCK FERT 58,900 € + 43,314 € Conditional lot release following deviation clearance (GxP review) QA11 W 1–3
Operational Instruction: Minor cosmetic packaging defect; close deviation CAPA and execute usage decision in QA11.
W1310109405 AQUASEPTIC PHARMA ORANGE BLOCK FERT 41,200 € + 29,560 € Label compliance rectification in Spain; instant market release QA11 / MB1B W 1–2
Operational Instruction: Apply compliant overlabel in Plant 1310 warehouse; unblock for Iberian healthcare distribution.
W0001121401 octenisept Antisep. Kath.Hbl. SS FERT 65,400 € + 24,343 € Seasonal safety buffer reduction for summer corridor MM02 W 2–4
Operational Instruction: Temporarily lower safety stock during summer low-infection months in MARC-EISBE.
W0001109155 mikrozid AF wipes Jumbo SS VERP 51,800 € + 23,278 € Safety adjustment to measured empirical packaging lead time MM02 W 2–3
Operational Instruction: Align canister buffer with verified 14-day vendor lead time instead of legacy 35-day default.
Phase 0 Data Deliverables & Artifacts

Curated Downloads & Working Files for Schülke Teams

Access exclusively the tactical deliverables, data gap dossiers, discovery questionnaires, and live CSV export files prepared for the Schülke & Mayr Supply Chain, QA, and IT Steering Committee.

Live Export

SAP MASS Execution File (.CSV)

Directly exports the 20 Quick Win material items with recalculated cash values based on the active simulator sliders. Semicolon-delimited for SAP MASS / LSMW upload.

Playbook & Guide

Quick Wins Playbook & Inactive Stock Guide

Operational guide covering the €7.41M inactive stock liquidation, STO intercompany routing rules, OTC pharmacy sell-off pricing, and FEFO allocation protocols.

Download Playbook (PDF)
Audit Dossier

Forensic Data Audit & Data Gaps Dossier

Exhaustive technical audit examining the 10 data omissions in NextGen Materialreport, hospital OTIF penalties, GxP risks, and exact SAP table joins for Phase 0.

Download Audit Dossier (PDF)
Questions Checklist

Technical Data Requirements & Discovery Questions

Complete 20-question discovery checklist categorized across Supply Chain, QA/GxP, Procurement/VMI, IT Architecture (SM36, SAP release), and Finance.

Download Questions (PDF)
Operational Brief

Customer Service & Dispatch Operations Brief

Simplified non-technical specification designed for Customer Service and Order Management leads, covering order delivery buffers and hospital emergency tranches.

Download Brief (PDF)
Executive Technical Memo

Executive Technical Briefing & Alignment Memo

Joint Technical Working Document & Bilingual Meeting Dossier for Jonas Stöckmann & Anna Sparty. Covers Dual-View architecture, SAP integration boundaries, and Top 20 Quick Wins roadmap.

Download Executive Briefing (PDF)
Commercial Offer & SOW

Enterprise Phase 0 Offer & SOW

Official commercial proposal for Phase 0 Discovery (€48,500 / 4–5 weeks), SLA definitions, GxP compliance guarantees, and target SC-DIO / OTIF milestones.

English (PDF) Deutsch (PDF)